• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?
RESEARCH UPDATE

Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?

October 1, 2022
Sibel Algon, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Dr. Algon, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Patel RS et al, J Child Adolesc Psychopharmacol 2021;31(8):521–530 

STUDY TYPE: Systemic review and meta-analysis

Pediatric bipolar depression (PBD) is difficult to treat (see Dr. Charuvastra’s article, "Bipolar Spectrum Disorders in Children and Adolescents," on page 1) and often broadly defined. Currently there are only two FDA-approved medications: lurasidone and olanzapine/fluoxetine combination (OFC). In this meta-analysis, researchers sought well-designed studies of second-generation antipsychotics (SGAs) to see if there are alternatives to the currently approved treatments. 

The authors reviewed randomized controlled trials comparing SGAs to placebo in youth (<20 years old) with PBD and used Children’s Depression Rating Scale-Revised scores to calculate treatment response and number needed to treat (NNT). Of 569 studies, only four met complete inclusion criteria—one of OFC, one of lurasidone, and two of quetiapine—and all four were industry funded. 

The meta-analysis included 826 youths with PBD who received short-term treatment (six to eight weeks) with an SGA or placebo. Only those administered lurasidone or OFC were significantly more likely than their placebo counterparts to be treatment responders. The NNT was 4.3 for lurasidone and 5.3 for OFC. A subgroup analysis found effect sizes for lurasidone treatment that were five-fold higher in older teens versus younger children (DelBello MP et al, J Am Acad Child Adolesc Psychiatry 2017;56(12):1015–1025). A subsequent meta-analysis of the same four trials reported that lurasidone was associated with smaller increases in weight, cholesterol, triglycerides, and prolactin compared to OFC (DelBello MP et al, J Am Acad Child Adolesc Psychiatry 2022;61(2):243–254). Quetiapine was not more effective than placebo for PBD. 

Carlat Take
While we accept that lurasidone has fewer metabolic side effects, we are wary of the other results. PBD remains a controversial diagnosis, widening the boundaries from classical bipolar disorder and likely including cases of oppositional-defiant disorder, disruptive mood dysregulation disorder, complex posttraumatic stress disorder, and borderline personality disorder. The four trials and this review come from authors who advocate for this PBD construct, and this heterogeneous mixture probably includes cases that are less responsive to SGAs. The other concern is that we have not seen the raw data, and industry-funded studies may manipulate research design. We need independent studies on treatment of classical bipolar I depression that are not industry funded to give us firmer guidance in this area. (Editor’s note: See “Reading Research: Details Matter” in The Carlat Child Psychiatry Report, July/Aug/Sept 2021.)

Child Psychiatry Research Update
KEYWORDS bipolar bipolar depression child psychiatry mood disorders research update
    Sibel Algon, MD.

    More from this author
    www.thecarlatreport.com
    Issue Date: October 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Note From the Editor-in-Chief
    Bipolar Spectrum Disorders in Children and Adolescents
    Assessing and Treating Catatonia in Children and Adolescents
    Assessing Sensory Processing Challenges
    Consider Catatonia in Your Differential
    SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?
    Pediatric Bipolar Depression: How Do We Rate a New Meta-Analysis?
    Ask the Editor: Is Silexan Safe for Children and Adolescents?
    CME Post-Test, Catatonia in Children and Adolescents, CCPR, Oct/Nov/Dec 2022
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.